腹腔静脉联合化疗对老年进展期结肠癌临床疗效观察  

Observation of the clinical efficacy of the intraperitoneal combined with intravenous chemotherapy for the elder patients with advanced colon cancer

作　　者：秦朝晖[1] 庄舜玖[1] 戚韶红[1] 李黎[1] 吴素芬[1] 

机构地区：[1]复旦大学附属华东医院,上海200040

出　　处：《上海医药》2007年第6期280-282,共3页Shanghai Medical & Pharmaceutical Journal

摘　　要：目的:观察腹腔静脉联合化疗对老年进展期结肠癌的临床疗效。方法:腹腔静脉联合化疗组40例采用氟脲苷、喜树碱腹腔化疗联合草酸铂、氟脲苷、CF静脉滴注方案,静脉化疗组40例采用草酸铂、氟脲苷、CF静脉滴注方案,4 wk为一疗程,连用6个疗程,然后评定疗效。结果:腹腔静脉联合化疗组40例,总有效率为65.0%,无进展中位生存期14.3个月;静脉联合化疗组总有效率为42.5%,无进展中位生存期10.8个月。两组有效率差异有统计学意义(P<0.05),联合化疗组无进展中位生存期优于对照组(P<0.05)。结论:腹腔静脉联合化疗是治疗老年进展期结肠癌的一种安全、有效的方法。Objective： To investigate the clinical efficacy of intraperitoneal combined with intravenous chemotherapy in the treatment of elderly patients with advanced colon cancer. Methods ： Forty patients in the combined chemotherapy group were given fluorouracil and camptothecin intraperitoneally combined with intravenous infusion of oxaliplatin, fluorouracil, and calcium folinate. Forty patients in intravenous chemotherapy group were administered oxaliplatin, fluorouracil, and calcium folinate intravenously. Four weeks as one cycle and six cycles were repeated. The clinical efficacy was evaluated. Results： The overall response rate was 65.0% in the combined chemotherapy group and 42.5% in the intravenous chemotherapy group. The progression - free median survival period was 14.3 months in the combined chemotherapy group and 10.8 months in the intravenous chemotherapy group. The difference was significant between the two groups （P 〈 0.05 ）. Conclusion ： Intraperitoneal combined with intravenous chemotherapy was safe and effective in the treatment of elderly patients with advanced colon cancer.

关 键 词：结肠癌 腹腔化疗 草酸铂 氟脲苷 亚叶酸钙 

分 类 号：R735.35[医药卫生—肿瘤]